Prior Authorization Form

Note: Please provide as much information as possible on this form. Missing data may cause processing delays for requested authorization(s). Attach additional sheets to this form if necessary.

Please fax the completed PA form and any additional informational sheets to Nirvanahealth at the following fax number: +1(866) 871-8565

Patient Information		Prescriber Information	
Patient Name:		Prescriber Name:	
Health Plan Name:		Prescriber Address:	
Patient Insurance Id:			
Patient Date of Birth:		Prescriber Phone:	( )
Patient Phone:		Prescriber Fax:	( )
		Prescriber Specialty:	
		Prescriber DEA:	
		Prescriber NPI:	

Medication & Medical Information	
Requested Drug(s) & Strength(s):	[ ] Verzenio 100 mg tablet [ ] Verzenio 150 mg tablet [ ] Verzenio 200 mg tablet [ ] Verzenio 50 mg tablet
Requested Daily Quantity Limit – Amount:	
Requested Daily Quantity Limit – Days:	
Requested Quantity Limit Over Time – Amount:	
Requested Quantity Limit Over Time – Days:	
Requested Quantity Per Rx – Amount:	
Expected Length of Therapy:	
Directions:	
Diagnosis and Diagnosis Codes (ICD-10 Standard Codes):	
List drugs used previously to treat the same condition:	
Additional clinical information or history. Please include any relevant test results and/or medical record notes:	

Questionnaire

Q1: I, as the provider or designated representative of the provider, certify and attest that the information provided is complete and accurate and that, upon request, I shall provide any information to RxAdvance that RxAdvance determines is reasonably necessary to verify my responses. (Check only one that apply)

[ ] Yes

[ ] No

Q2: Is the member currently treated with this medication? (Check only one that apply)

[ ] Yes (please list start date of therapy (month/day/year)) _____

(*Required)

[ ] No

Q3: What is the member's diagnosis? (Check only one that apply)

[ ] Advanced or Metastatic Breast Cancer

[ ] Early Breast Cancer

[ ] Other (please specify the member's diagnosis and provide clinical rationale for the request) _____(*Required)

Q4: What is the member's diagnosis? (Check only one that apply)

[ ] Advanced or Metastatic Breast Cancer

[ ] Early Breast Cancer

[ ] Other (please specify the member's diagnosis and provide clinical rationale for the request) _____(*Required)

Q5: Is the disease hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative? (Check only one that apply)

[ ] Yes

[ ] No (please provide clinical rationale for the request) _____ (*Required)

Q6: Is the requested medication used in combination with an aromatase inhibitor (e.g., Arimidex [anastrozole], Aromasin [exemestane], Femara [letrozole])? (Check only one that apply)

[ ] Yes

[ ] No

Q7: Is the member postmenopausal woman or male? (Check only one that apply)

[ ] Yes

[ ] No (please provide clinical rationale for the request) _____ (*Required)

Q8: Is the requested medication used in combination with Faslodex (fulvestrant)? (Check only one that apply)

[ ] Yes

[ ] No

Q9: Has the disease progressed following endocrine therapy? (Check only one that apply)

[ ] Yes

[ ] No (please provide clinical rationale for the request) _____ (*Required)

Q10: Is the requested medication used as monotherapy? (Check only one that apply)

[ ] Yes

[ ] No (please provide clinical rationale for the request) _____ (*Required)

Q11: Has the disease progressed following endocrine therapy? (Check only one that apply)

[ ] Yes

[ ] No (please provide clinical rationale for the request) _____ (*Required)

Q12: patient has already received at least one prior chemotherapy regimen (Check only one that apply)

[ ] Yes (please specify regimen and start and end date of therapy (mm/dd/yy))

[ ] No (please provide clinical rationale for the request) _____ (*Required)

Q13: Does the member have diagnosis of early breast cancer at high risk of recurrence? (Check only one that apply)

[ ] Yes

[ ] No (please provide clinical rationale for the request) _____ (*Required)

Q14: Is the disease hormone receptor (HR)-positive? (Check only one that apply)

[ ] Yes

[ ] No (please provide clinical rationale for the request) _____ (*Required)

Q15: Is the disease human epidermal growth factor receptor 2 (HER2)-negative? (Check only one that apply)

[ ] Yes

[ ] No (please provide clinical rationale for the request) _____ (*Required)

Q16: Is the disease node-positive? (Check only one that apply)

[ ] Yes

[ ] No (please provide clinical rationale for the request) _____ (*Required)

Q17: Is the requested medication used as adjunctive therapy? (Check only one that apply)

[ ] Yes

[ ] No (please provide clinical rationale for the request) _____ (*Required)

Q18: Is the prescribed medication used in combination with tamoxifen or aromatase inhibitor (e.g., anastrozole, letrozole, exemestane)? (Check only one that apply)

[ ] Yes (please specify drug name) _____(*Required)

[ ] No (please provide clinical rationale for the request) _____ (*Required)

Q19: Dose the member have a Ki-67 score of greater than or equal to 20% as determined by an FDA approved test or a test performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA)? (Check only one that apply)

[ ] Yes (please specify test name and date of test) _____(*Required)

[ ] No (please provide clinical rationale for the request) _____
(*Required)

Q20: Is the requested medication prescribed by or in consultation with an oncologist? (Check only one that apply)

[ ] Yes

[ ] No (please provide clinical rationale for the request) _____
(*Required)

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, Insurer, Medical Group or its designated representatives may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Signature of Prescriber or Authorized Representative:	Date:
Print Authorized Representative Name:	